Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
---|
04/20/2011 | EP2311952A2 Antibodies to MRT-1 protein or fragments thereof |
04/20/2011 | EP2311951A1 Novel MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1 |
04/20/2011 | EP2311950A1 Novel MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1 |
04/20/2011 | EP2311944A1 Polypeptides and polynucleotides from coagulase-negative staphylococci |
04/20/2011 | EP2311943A2 Factor VII glycoforms |
04/20/2011 | EP2311882A1 Reducing the immunogenicity of fusion proteins |
04/20/2011 | EP2311872A1 Albumin fusion proteins |
04/20/2011 | EP2311870A1 Compositions and methods for the treatment of immune related diseases |
04/20/2011 | EP2311869A1 Use of mammalian cytokine; related reagents |
04/20/2011 | EP2311868A1 Compositions and methods for the treatment of immune related diseases |
04/20/2011 | EP2311867A1 Trimeric binding proteins for trimeric cytokines |
04/20/2011 | EP2311866A1 GAG binding proteins |
04/20/2011 | EP2311864A1 Recombinant protein-s composition |
04/20/2011 | EP2311863A1 Nucleic acid and corresponding protein entitled 121P1F1 useful in treatment and detection of cancer |
04/20/2011 | EP2311862A2 Differential in tumour gene products and use of same |
04/20/2011 | EP2311861A2 Differential in tumour gene products and use of same |
04/20/2011 | EP2311860A2 Differential in tumour gene products and use of same |
04/20/2011 | EP2311854A1 Mutated pseudomonas exotoxins with reduced antigenicity |
04/20/2011 | EP2311852A1 Anti-infarction molecules |
04/20/2011 | EP2311851A2 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
04/20/2011 | EP2311850A1 Anti-cancer cyclopenta[g]quinazoline compounds |
04/20/2011 | EP2311849A1 Specific binding agents of human angiopoietin-2 |
04/20/2011 | EP2311532A1 Anti-viral griffithsin compounds, compositions, and methods of use |
04/20/2011 | EP2311531A1 Anti-viral griffithsin compounds, compositions, and methods of use |
04/20/2011 | EP2311495A1 Vascularization inhibitors |
04/20/2011 | EP2311490A2 Uses of antibodies to aminophospholipids for cancer treatment |
04/20/2011 | EP2311486A1 GLP-2 for use in intestine and muscle recovery |
04/20/2011 | EP2311485A1 Thymosin beta 4 promotes wound repair |
04/20/2011 | EP2311484A1 Use of IL-12 and IL-12 antagonists for the manufacture of a pharmaceutical composition for the treatment of autoimmune diseases |
04/20/2011 | EP2311483A1 GCSF for use in treating a neurological disease with pathophysiological mechanisms involving ischemia or hypoxia |
04/20/2011 | EP2311482A1 Osteogenic synthetic BMP-7 peptides, pharmaceutical compositions cell culture medium containing same |
04/20/2011 | EP2311481A2 Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor |
04/20/2011 | EP2311480A1 Compstatin analogs with improved activity |
04/20/2011 | EP2311479A1 Compstatin analogs with improved activity |
04/20/2011 | EP2311478A1 Use of ip3 receptor-binding protein for controlling intracellular pH |
04/20/2011 | EP2311477A1 Use of ip3 receptor-binding protein for controlling phosphatidylinositol metabolism |
04/20/2011 | EP2311471A2 Regeneration and augmentation of bone using mesenchymal stem cells |
04/20/2011 | EP2311469A2 Methods and compositions for tissue regeneration |
04/20/2011 | EP2311468A1 Gene overexpressed in cancer |
04/20/2011 | EP2311460A1 Oxymorphone controlled release formulations |
04/20/2011 | EP2311437A1 Stabilised compositions of factor VII polypeptides |
04/20/2011 | EP2311436A1 Stabilized protein crystals, formulations containing them and methods of making them |
04/20/2011 | EP2311432A1 Prevention and reduction of blood loss |
04/20/2011 | EP2311323A1 Compositions and methods for degradation of protein deposits and prions |
04/20/2011 | EP2310523A1 Methods for enhanced production of bone morphogenetic proteins |
04/20/2011 | EP2310509A1 Tnfsf single chain molecules |
04/20/2011 | EP2310508A1 Tgf-b antagonist multi-target binding proteins |
04/20/2011 | EP2310417A1 Oxidized ldl specific antibody-fusion and conjugated proteins |
04/20/2011 | EP2310408A2 Thyroid stimulating hormone fusion proteins |
04/20/2011 | EP2310405A1 Peptide inhibitors of cd40l signaling and uses therefor |
04/20/2011 | EP2310402A1 Bridged secondary amines and use thereof as iap bir domain binding compounds |
04/20/2011 | EP2310095A1 Macrocyclic quinoxaline compounds as hcv ns3 protease inhibitors |
04/20/2011 | EP2310062A1 Use of immobilized antagonists for enhancing growth factor containing bioimplant effectiveness |
04/20/2011 | EP2310061A2 Isolated extracellular matrix material including subserous fascia |
04/20/2011 | EP2310054A2 Aptamer inhibition of thrombus formation |
04/20/2011 | EP2310044A2 Anti-tumor immunotherapy |
04/20/2011 | EP2310043A1 Von willebrand factor or factor viii and von willebrand factor for the treatment of coagulopathy induced by inhibitors of thrombocytes |
04/20/2011 | EP2310042A1 Use of pasireotide for the treatment of endogenous hyperinsulinemic hypoglycemia |
04/20/2011 | EP2310041A2 Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease |
04/20/2011 | EP2310040A1 Method to stimulate immune function and regeneration |
04/20/2011 | EP2310039A1 Fgf-9 and its use relating to blood vessels |
04/20/2011 | EP2310038A2 Treatment of hearing and balance impairments using compounds having erythropoietin activity |
04/20/2011 | EP2310037A2 Conglutin-gamma as medicament and diet supplement |
04/20/2011 | EP2310036A1 System for the determination of molecules altering the function of interferon, method therefor and compounds altering interferon activity |
04/20/2011 | EP2310035A2 Fibroblast growth factor (fgf) analogs and uses thereof |
04/20/2011 | EP2310034A2 Compounds for treating beta-amyloidoses |
04/20/2011 | EP2310033A2 Compounds for treating amyloidoses |
04/20/2011 | EP2310032A2 Compounds for treating symptoms associated with parkinson's disease |
04/20/2011 | EP2310031A1 Combination of a tiliroside and a peptide |
04/20/2011 | EP2310030A2 Novel antiviral peptides against influenza virus |
04/20/2011 | EP2310029A2 Suppression of cancers |
04/20/2011 | EP2310028A2 Suppression of neuroendocrine diseases |
04/20/2011 | EP2310018A1 Use of nifurtimox for treating giardiasis |
04/20/2011 | EP2309982A2 Controlled release copolymer formulation with improved release kinetics |
04/20/2011 | EP2309979A1 Delivery of dry formulations of octreotide |
04/20/2011 | EP2309975A2 Use of plant-derived recombinant growth factors in skin care |
04/20/2011 | EP1938774B1 Medical artificial nerve graft containing silk fibroin and its preparation method |
04/20/2011 | EP1670926B1 Modified cea /b7 vector |
04/20/2011 | EP1648485B1 Formulation for a protein pharmaceutical without added human serum albumin (hsa) |
04/20/2011 | EP1578361B1 Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence |
04/20/2011 | EP1572734B1 Peptides impairing pbx dependent gene regulation |
04/20/2011 | EP1511471B9 Colloidal suspension of submicronic particles for delivering active principles and method for preparing same |
04/20/2011 | EP1505963B1 Hepatitis c virus inhibitors |
04/20/2011 | EP1082415B1 Methods useful for modulation of angiogenesis using tyrosine kinase src |
04/20/2011 | EP1000167B2 Production of human mutant proteins in human cells by homologous recombination |
04/20/2011 | CN1964737B Methods of using IL-1 antagonists to treat autoinflammatory disease |
04/20/2011 | CN1849395B HLA-a24 binding cancer antigen peptide derived from ribin |
04/20/2011 | CN1701117B Antibody against enzyme specifically cleaving VON WILLEBRAND factor and assay system using the same |
04/20/2011 | CN102027123A Recombinant production of authentic human proteins using human cell expression systems |
04/20/2011 | CN102027122A A method for the production of a human protein in a plant, in particular a human recombinant lysosomal enzyme in a cereal endosperm |
04/20/2011 | CN102027114A Articular cartilage gene therapy with recombinant vector encoding BMP-7 |
04/20/2011 | CN102027110A Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof |
04/20/2011 | CN102027007A Long-acting Y2 and/or Y4 receptor agonists |
04/20/2011 | CN102027006A Novel and powerful MHC-class II petptides derived from survivin |
04/20/2011 | CN102026656A Method of promoting wound healing |
04/20/2011 | CN102026655A Lipocalin-2 as a prognostic and diagnostic marker for heart and stroke risks |
04/20/2011 | CN102026654A Oxygen-transferring blood substitute and a pharmaceutical composition (variants) |
04/20/2011 | CN102026653A Human factor IX variants with an extended half life |
04/20/2011 | CN102026652A Thrombin inhibitor |
04/20/2011 | CN102026651A Method for achieving desired glial growth factor 2 plasma levels |